The Role of Swan-Ganz Catheter in Hemodynamic Resuscitation for Patients With Cardiogenic Shock

Recruiting now · Not applicable

Conditions studied: Cardiogenic Shock, Pulmonary Artery Catheter Waveform Interpretation, Hemodynamic Management, Hemodynamic Optimization, Hemodynamic Monitoring, Acute Myocardial Infarction (AMI), Critical Care, Intensive Care, Emergency, Cardio Vascular Disease

In brief

This clinical trial examines whether the use of the Swan-Ganz catheter, a specialized pulmonary artery catheter, can improve hemodynamic management and treatment outcomes in patients experiencing cardiogenic shock due to acute myocardial infarction (AMI). Cardiogenic shock is a critical condition marked by the heart's inability to supply adequate blood to the organs, often resulting from a severe heart attack. Despite advancements in care, the condition remains associated with high mortality. Effective monitoring of cardiovascular status is crucial in guiding timely and tailored treatment decisions. Participants in this study will undergo advanced hemodynamic monitoring using the Swan-Ganz catheter, which provides continuous data on cardiac output and other key parameters. This information enables physicians to better assess circulatory function and adjust therapies accordingly. The research will evaluate clinical characteristics, response to treatment, and 30-day outcomes in patients managed with this technique. The study also aims to identify factors associated with successful hemodynamic stabilization and potential complications related to catheter use. A total of 108 adult patients meeting specific eligibility criteria will be enrolled at Bach Mai Hospital over 3 years. Participation is voluntary, and all patients will continue to receive standard-of-care treatment. All personal and medical data will be handled with strict confidentiality.

Key facts

Study ID: NCT07062744
Run by: Bach Mai Hospital
People needed: 108
Starts: 2025-05-27
Expected to finish: 2027-12-30
Last updated by the study team: 2025-07-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Age ≥ 18 years.
Provided written informed consent to participate in the study.
Diagnosed with cardiogenic shock due to acute myocardial infarction according to IABP-SHOCK II (2012) criteria:
Systolic blood pressure (SBP) < 90 mmHg for at least 30 minutes, or requiring vasopressor agents to maintain SBP > 90 mmHg.
Evidence of end-organ hypoperfusion, indicated by at least one of the following: Altered mental status, Urine output < 30 mL/hour, Cold extremities with mottled skin, Serum lactate level > 2 mmol/L.

You may not qualify if…

Presence of cervical cellulitis.
Inability to identify neck anatomy or history of cervical radiotherapy.
Coagulopathy (INR > 1.5 and/or platelet count < 50 G/L).
End-stage chronic diseases, including: Advanced malignancy, advanced-stage HIV, bedridden patients for more than 3 months, decompensated liver cirrhosis (Child-Pugh class C).
Patients with cardiac arrest or mechanical complications such as myocardial rupture prior to Swan-Ganz catheterization.
Congenital heart defects or intracardiac shunts. Refusal of participation by the patient or their legal representative.

Where it is running

BachMai Hospital, Hanoi Medical University — Hanoi, Vietnam (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.